Role of gut microbiota and tryptophan metabolism in nonalcoholic fatty liver disease
10.3969/j.issn.1001-5256.2022.06.040
- VernacularTitle:肠道菌群和色氨酸代谢在非酒精性脂肪性肝病中的作用
- Author:
Qingling ZHONG
1
,
2
;
Liangping LI
2
Author Information
1. School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China
2. Department of Gastroenterology, Sichuan Provincial People's Hospital & The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610072, China
- Publication Type:Reviews
- Keywords:
Non-alcoholic Fatty Liver Disease;
Gastrointestinal Microbiome;
Tryptophan
- From:
Journal of Clinical Hepatology
2022;38(6):1411-1415
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is a manifestation of multi-system dysfunction involving the liver, ranging from simple hepatic steatosis to nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. An increasing number of studies have shown the importance of the changes in gut microbiota dysbiosis and its metabolites in NAFLD. Tryptophan and its derivatives produced by gut microbiota have the effects on improving intestinal barrier function, regulating abnormal glucose and lipid metabolism, and alleviating insulin resistance and inflammatory response. This article reviews gut microbiota, tryptophan and its metabolites, and the effect of their interaction on NAFLD.
